Zinzino group revenue increased with a total of 10%, compared with the previous year.

The revenue in July for Zinzino's sales markets increased by 10% and amounted to SEK 105.9 (96.6) million. Faun Pharma's external sales increased by 14% and amounted to SEK 3.3 (2.9) million. Overall, the Group increased revenues by 10% to SEK 109.2 (99.5) million compared with the previous year.

Accumulated revenue for January - July 2022 increased by 2% to SEK 773.1 (755.3) million.

Revenues were distributed as follows:

Regions, mSEK22-July21-JulyChangeYTD 2022YTD 2021Change
The Nordics 26.5 28.6 -7% 182.6 215.4 -15%
Central Europe 22.1 17.9 23% 146.0 125.8 16%
East Europe 24.4 24.9 -2% 184.5 185.3 0%
South & West Europe 12.3 10.8 14% 87.0 81.3 7%
The Baltics 5.8 5.4 7% 40.5 41.0 -1%
North America 6.3 4.0 58% 38.9 29.1 34%
Asia-Pacific 7.6 5.0 52% 41.9 41.2 2%
Africa 0.9 0.04.1 0.0
Zinzino105.996.610%725.5719.11%
Faun Pharma 3.3 2.9 14% 47.6 36.2 31%
Zinzino Group109.299.510%773.1755.32%

Countries in regions:

-The Nordics: Denmark, Faroe Island, Finland, Iceland, Norway, Sweden

-Central Europe: Austria, Germany, Switzerland

-East Europe: Czech Republic, Slovakia, Hungary, Poland, Romania

-South & West Europe: Cyprus, France, Greece, Italy, Netherlands, Spain, United Kingdom, Belgium, Ireland

-The Baltics: Estonia, Latvia, Lithuania

-North America: Canada, USA

-Asia-Pacific: Australia, Hong Kong, India, Malaysia, Singapore, Taiwan, Thailand

-Africa: South Africa

For more information:

Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, zinzino.com

Pictures for publication free of charge:

marketing@zinzino.com

Certified Adviser: Erik Penser Bank Aktiebolag, +46 (0) 8 463 83 00, email: certifiedadviser@penser.se        

Zinzino AB (publ) is obliged to publish this information in compliance with current EU regulations governing market abuse. The information was provided by the above contact person for publication at 14:00 the 3rd of August 2022.

Zinzino is a global direct sales company from Scandinavia specializing in test-based, personalized nutrition. It is a public limited company with its shares listed on Nasdaq First North Premier Growth Market. Their scientifically proven nutritional supplements are available on more than 100 markets across the world. Zinzino owns the Norwegian research and production units BioActive Foods AS and Faun Pharma AS. The company headquarters is in Gothenburg, Sweden with additional offices in Europe, Asia, the US and Australia.

https://news.cision.com/zinzino/r/zinzino-ab--publ--preliminary-sales-report-july-2022,c3609831

https://mb.cision.com/Main/10976/3609831/1611346.pdf

(c) 2022 Cision. All rights reserved., source Press Releases - English